Drug intelligence / Profile preview

ribavirin monophosphate

Development stage
Unknown
Lead developer
Valeant Pharmaceuticals
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
None (not Administered Directly As A Pharmaceutical Agent; Formed In Vivo From Parent Compound)
01

Overview

Ribavirin monophosphate is the phosphorylated metabolite of the antiviral drug ribavirin. It is a synthetic guanosine nucleoside analog that acts as a competitive inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH), mimicking inosine 5′-monophosphate. This inhibition disrupts de novo synthesis of guanine nucleotides and decreases intracellular GTP pools, leading to reduced viral protein synthesis and limited replication of viral genomes[1][4]. Ribavirin itself is used as an antiviral agent against several RNA and DNA viruses—primarily hepatitis C virus (in combination with interferon) and certain viral hemorrhagic fevers[1][2][4]. Ribavirin monophosphate is not administered directly as a drug but represents an active intermediate in the metabolic pathway of orally or parenterally administered ribavirin.

Other names
ribavirin monophosphatevirazole 5'-phosphateribavirin-5'-phosphateribavirin 5'-monophosphate
02

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on ribavirin monophosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ribavirin monophosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call